Heart failure and diabetes: metabolic alterations and therapeutic interventions: a state-of-the-art review from the Translational Research Committee of the Heart Failure Association-European Society of Cardiology.
Heart failure and diabetes: metabolic alterations and therapeutic interventions: a state-of-the-art review from the Translational Research Committee of the Heart Failure Association-European Society of Cardiology.
复制标题
DOI：
10.1093/eurheartj/ehy596
复制
发表时间：
2018-12-21
影响因子：
39.3
通讯作者：
Heymans S
中科院分区：
文献类型：
--
作者：
Maack C;Lehrke M;Backs J;Heinzel FR;Hulot JS;Marx N;Paulus WJ;Rossignol P;Taegtmeyer H;Bauersachs J;Bayes-Genis A;Brutsaert D;Bugger H;Clarke K;Cosentino F;De Keulenaer G;Dei Cas A;González A;Huelsmann M;Iaccarino G;Lunde IG;Lyon AR;Pollesello P;Rena G;Riksen NP;Rosano G;Staels B;van Laake LW;Wanner C;Farmakis D;Filippatos G;Ruschitzka F;Seferovic P;de Boer RA;Heymans S
心力衰竭(HF)正在发展为一种现代流行病，尽管治疗取得了进展，但它仍然带有不祥的预后和重大的社会经济负担。1许多作为前景看好的HF药物出现的新药未能改善残余发病率和死亡率。2、3由于开发和测试新药的成本越来越高，4重新调整现有药物的用途以适应新的适应症的概念变得相当重要。从概念上讲，2型糖尿病(T2 DM)、肥胖或慢性肾脏疾病等在心力衰竭人群中高度流行的共病，已经从无辜的旁观者转变为心力衰竭的驱动者。这尤其适用于射血分数保留(HFpEF)的心力衰竭，这种表型占心力衰竭患者的50%以上，目前还没有有效的治疗方法。5、6特别是T2 DM的患病率，从而其合并心力衰竭迅速增加，主要是由于肥胖的流行。T2 DM的临床研究越来越多，主要是作为抗糖尿病药物的安全终点。其中一些药物具有有益的心血管效应，而不是依赖于它们的降糖作用。因此，抗糖尿病药物因其在心力衰竭治疗中的潜在再利用而受到人们的关注。在此背景下，欧洲心脏病学会(ESC)心力衰竭协会(HFA)的翻译研究委员会组织了一次关于HF和T2 DM的研讨会，重点讨论这种关系的病理生理和治疗方面。在这里，我们总结了在这次研讨会上提出的主要观点，提供了当前证据和未决问题的概述。
Heart failure (HF) is growing to a modern epidemic and despite advances in therapy, it still carries an ominous prognosis and a significant socioeconomic burden. 1 Many novel agents that emerged as promising HF drugs failed to improve residual morbidity and mortality. 2, 3 Since developing and testing new agents has become increasingly costly, 4 the concept of repurposing existing drugs for new indications has gained considerable importance. Conceptually, comorbidities such as type 2 diabetes mellitus (T2DM), obesity or chronic kidney disease, all highly prevalent in HF populations, have shifted from being innocent bystanders to drivers of HF. This applies especially to HF with preserved ejection fraction (HFpEF), a phenotype that accounts for more than 50% of HF patients and for which no effective therapy exists thus far. 5, 6 In particular, the prevalence of T2DM, thereby its combination with HF is rapidly increasing, mainly due to the obesity epidemic. Cardiovascular (CV) outcomes are addressed by an increasing number of clinical studies in T2DM, mainly as safety endpoints for anti-diabetic agents. Some of those drugs have beneficial CV effects independent of their glucose-lowering action. Consequently, antidiabetic agents have gained interest for their potential repurposing in HF treatment. In this context, the Translational Research Committee of the Heart Failure Association (HFA) of the European Society of Cardiology (ESC) organized a workshop on HF and T2DM, focusing on the pathophysiological and therapeutic aspects of this relationship. Here, we summarize the main points raised during this workshop, providing an overview of current evidence and open issues.
登录
查看更多内容
影响因子：
8.2
作者：
Bugger, Heiko;Abel, E. Dale
通讯作者：
Abel, E. Dale
影响因子：
3
作者：
Chen, Jingjing;Wang, Dandan;Huang, Congxin
通讯作者：
Huang, Congxin
DOI：
10.1161/circheartfailure.110.952556
发表时间：
2011-01
期刊：
Circulation. Heart failure
影响因子：
--
作者：
Aguilar D;Chan W;Bozkurt B;Ramasubbu K;Deswal A
通讯作者：
Deswal A
DOI：
10.1111/dom.12572
发表时间：
2015-12
期刊：
Diabetes, obesity & metabolism
影响因子：
--
作者：
Chilton R;Tikkanen I;Cannon CP;Crowe S;Woerle HJ;Broedl UC;Johansen OE
通讯作者：
Johansen OE
影响因子：
24
作者：
Aguilar, David;Bozkurt, Biykem;Ramasubbu, Kumudha;Deswal, Anita
通讯作者：
Deswal, Anita